In this vein, asoprisnil, a steroidal 11β-benzaldoxime-substituted selective progesterone receptor modulator (SPRM), targets TGFB3 and TGFBR2 in leiomyoma cells but not normal myometrial cells [97], providing a potentially effective treatment option for leiomyoma. The gene discussed is TGFB3; the disease is leiomyoma.